Treats insomnia characterized. ANDA 213592, held by Breckenridge. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 213592 (Zolpidem Tartrate), held by Breckenridge, was first approved by FDA on Jun 4, 2020, with 1 approved supplement and 0 published complete response letters.
Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2020 | Original application | Approved | None posted |
| Zolpidem Tartrate6.25MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate12.5MG · tablet, extended release;oral | Zolpidem Tartrate | Rx |
| Nov 21, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 4, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters